Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Therapeutic drug monitoring of infliximab and adalimumab in adult inflammatory bowel disease
NL-OMON29021Unknown
- Sponsor
- Noordwest Ziekenhuisgroep
- Start
- Nov 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Open-label trial of infliximab and adalimumab in inflammatory bowel disease (IBD), Crohn's disease and autoimmune colitis (2 cohorts), sponsored by Noordwest Ziekenhuisgroep. Status: unknown.
02
Drugs
infliximabadalimumab
03
Conditions
inflammatory bowel disease (IBD)Crohn's diseaseautoimmune colitis
Beyond the preview
Go deeper on NL-OMON29021.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON29021.